Sahin et al. recently reported interim data from a phase 1 clinical trial (NCT02410733) treating melanoma patients with a RNA-lipoplex vaccine (RNA-LPX), targeting melanoma TAA.1 The trial is a multicenter, non-randomized, open-label, dose-escalation trial designed to evaluate the safety and tolerability of BNT111 targeting four melanoma TAA (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE). The gene discussed is MAGEA3; the disease is melanoma.